A Phase 1, Open-label Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on the Single-dose Pharmacokinetics of Rilematovir
Latest Information Update: 21 Feb 2022
At a glance
- Drugs Rilematovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 16 Feb 2022 Status changed from recruiting to completed.
- 15 Dec 2021 New trial record